KAI-YIU YEUNG, M.D., F.R.C.P. (C); MILTON CORN, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Piperacetazine, a piperidine derivative of phenothiazine introduced in 1961 for treatment of schizophrenia, has been shown to be an effective tranquilizer, safe for short- and long-term therapy. Reported hematologic complications have been infrequent and restricted to mild transient decrease in hemoglobin (one case) (1); and reversible leukopenia and thrombocytopenia (2). Recently, we saw a patient who developed fatal aplastic anemia receiving piperacetazine, and no other medication, for 17 months. Review of the English journal literature and personal communication with Dow Chemical Company1 uncovered no previous report of this association. We, therefore, report this case to
YEUNG K, CORN M. Fatal Aplastic Anemia with Piperacetazine Therapy. Ann Intern Med. ;81:411. doi: 10.7326/0003-4819-81-3-411
Download citation file:
Published: Ann Intern Med. 1974;81(3):411.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use